WO2015071841A1 - Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them - Google Patents
Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them Download PDFInfo
- Publication number
- WO2015071841A1 WO2015071841A1 PCT/IB2014/065992 IB2014065992W WO2015071841A1 WO 2015071841 A1 WO2015071841 A1 WO 2015071841A1 IB 2014065992 W IB2014065992 W IB 2014065992W WO 2015071841 A1 WO2015071841 A1 WO 2015071841A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- complex
- dabigatran
- sodium
- diseases
- acetate
- Prior art date
Links
- 229960003850 dabigatran Drugs 0.000 title claims abstract description 72
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 title claims abstract description 72
- 238000000034 method Methods 0.000 title claims abstract description 28
- 230000008569 process Effects 0.000 title claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 5
- KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 claims abstract description 61
- 229960000288 dabigatran etexilate Drugs 0.000 claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 29
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 27
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 24
- 238000010668 complexation reaction Methods 0.000 claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 206010003658 Atrial Fibrillation Diseases 0.000 claims abstract description 14
- 229960004951 dabigatran etexilate mesylate Drugs 0.000 claims abstract description 14
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 13
- 206010061216 Infarction Diseases 0.000 claims abstract description 12
- 206010003119 arrhythmia Diseases 0.000 claims abstract description 12
- 230000000747 cardiac effect Effects 0.000 claims abstract description 12
- 230000007574 infarction Effects 0.000 claims abstract description 12
- 230000000771 oncological effect Effects 0.000 claims abstract description 12
- 238000011321 prophylaxis Methods 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 230000008506 pathogenesis Effects 0.000 claims abstract description 11
- 238000010521 absorption reaction Methods 0.000 claims abstract description 10
- 150000002148 esters Chemical class 0.000 claims abstract description 9
- 230000009467 reduction Effects 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 24
- 238000009472 formulation Methods 0.000 claims description 19
- 230000035699 permeability Effects 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 12
- 239000000084 colloidal system Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 239000003125 aqueous solvent Substances 0.000 claims description 10
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 10
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 10
- 238000013149 parallel artificial membrane permeability assay Methods 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 10
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 10
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 9
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 9
- 229920001577 copolymer Polymers 0.000 claims description 9
- 229920000578 graft copolymer Polymers 0.000 claims description 9
- 229920001983 poloxamer Polymers 0.000 claims description 9
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 229940117958 vinyl acetate Drugs 0.000 claims description 9
- 229920002554 vinyl polymer Polymers 0.000 claims description 9
- 239000013543 active substance Substances 0.000 claims description 8
- 239000006185 dispersion Substances 0.000 claims description 8
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 claims description 7
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 7
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 235000017281 sodium acetate Nutrition 0.000 claims description 7
- 239000001632 sodium acetate Substances 0.000 claims description 7
- 229960004249 sodium acetate Drugs 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000011200 topical administration Methods 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- 238000001228 spectrum Methods 0.000 claims description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 3
- 229910016860 FaSSIF Inorganic materials 0.000 claims description 3
- 229910005429 FeSSIF Inorganic materials 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 230000000112 colonic effect Effects 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 abstract description 15
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 10
- 239000003146 anticoagulant agent Substances 0.000 abstract description 8
- 229940127219 anticoagulant drug Drugs 0.000 abstract description 8
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract description 7
- 239000002552 dosage form Substances 0.000 abstract description 7
- 235000002906 tartaric acid Nutrition 0.000 abstract description 7
- 239000011975 tartaric acid Substances 0.000 abstract description 7
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 239000002253 acid Substances 0.000 abstract description 4
- 230000007423 decrease Effects 0.000 abstract description 3
- 239000002775 capsule Substances 0.000 description 16
- 208000032843 Hemorrhage Diseases 0.000 description 15
- 208000034158 bleeding Diseases 0.000 description 14
- 231100000319 bleeding Toxicity 0.000 description 14
- 229940066336 pradaxa Drugs 0.000 description 13
- 208000006011 Stroke Diseases 0.000 description 10
- -1 hexyloxycarbonyl carbamide Chemical compound 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 229930182480 glucuronide Natural products 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 3
- 229960005080 warfarin Drugs 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 150000008134 glucuronides Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 239000012798 spherical particle Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940033134 talc Drugs 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003868 thrombin inhibitor Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- GNENVASJJIUNER-UHFFFAOYSA-N 2,4,6-tricyclohexyloxy-1,3,5,2,4,6-trioxatriborinane Chemical compound C1CCCCC1OB1OB(OC2CCCCC2)OB(OC2CCCCC2)O1 GNENVASJJIUNER-UHFFFAOYSA-N 0.000 description 1
- NOHUXXDTQJPXSB-UHFFFAOYSA-N 2-acetyloxybenzoic acid;2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 NOHUXXDTQJPXSB-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 229940123900 Direct thrombin inhibitor Drugs 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108010080798 N(alpha)-(2-naphthylsulfonylglycyl)-4-amidinophenylalanine piperidide Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940003558 aggrenox Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 229940051147 fd&c yellow no. 6 Drugs 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 description 1
- 235000012738 indigotine Nutrition 0.000 description 1
- 239000004179 indigotine Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- XXTWZTPVNIYSJZ-DEOSSOPVSA-N n-[(2s)-3-(4-carbamimidoylphenyl)-1-oxo-1-piperidin-1-ylpropan-2-yl]-2-(naphthalen-2-ylsulfonylamino)acetamide Chemical compound C1=CC(C(=N)N)=CC=C1C[C@@H](C(=O)N1CCCCC1)NC(=O)CNS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 XXTWZTPVNIYSJZ-DEOSSOPVSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Optics & Photonics (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to pharmaceutically acceptable complex formulae comprising complexes of Dabigatran, its esters, preferably Dabigatran etexilate, its salts, preferably 5 Dabigatran etexilate mesylate, or derivatives thereof and complexation agents and pharmaceutically accepted excipients, process for the preparation thereof and pharmaceutical compositions containing them. The complex formulae of the present invention have improved physicochemical properties and enhanced biological performance and are useful in the treatment and/or prophylaxis of diseases, in particular thrombotic diseases, stroke, cardiac infarction and/or atrial fibrillation and cardiac arrhythmia, as well as oncological diseases of any pathogenesis. More specifically, the complex of the present invention possesses increased apparent solubility in the whole physiologically relevant pH range resulting in increased absorption and higher overall bioavailability. This allows the reduction of dose which delivers significantly less anticoagulant to the GI tract. Furthermore, the complex composition of the present invention contains no tartaric acid or any other acid which further decreases the incidence of GI tract bleeding. This also makes the bioavailability of the compound independent of the way it is administered; the final dosage form is not sensitive to being broken, chewed, or opened. Overall, the complex Dabigatran composition of the present invention allows safer administration of a lower dose from the active ingredient.
Description
COMPLEXES OF DABIGATRAN AND ITS DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS
CONTAINING THEM
FIELD OF THE INVENTION
The invention is directed to a stable complex with increased apparent solubility and increased dissolution rate comprising as active compound Dabigatran, its esters, preferably Dabigatran etexilate, its salts, preferably Dabigatran etexilate mesylate, or derivatives thereof, which is useful in the treatment and/or prophylaxis of diseases, in particular thrombotic diseases, stroke, cardiac infarction and/or atrial fibrillation and cardiac arrhythmia, as well as oncological diseases of any pathogenesis. More specifically, the complex of the present invention possesses increased apparent solubility in the whole physiologically relevant pH range resulting in increased absorption and higher overall bioavailability. This allows the reduction of dose which delivers significantly less anticoagulant to the GI tract. Furthermore, the complex Dabigatran, its esters, preferably Dabigatran etexilate, its salts, preferably Dabigatran etexilate mesylate, or derivatives thereof of the present invention contains no tartaric acid or any other acid which further decreases the incidence of GI tract bleeding. This also makes the bioavailability of the compound independent of the way it is administered; the final dosage form is not sensitive to being broken, chewed, or opened. Overall, the complex Dabigatran, its esters, preferably Dabigatran etexilate, its salts, preferably Dabigatran etexilate mesylate, or derivatives thereof of the present invention allows safer administration of a lower dose from the active ingredient.
BACKGROUND OF THE INVENTION
Background Regarding Dabigatran Dabigatran was discovered from a panel of chemicals with similar structure to benzamidine- based thrombin inhibitor a-NAPAP (N-alpha-(2-naphthylsulfonylglycyl)-4- amidinophenylalanine piperidide), which had been known since the 1980s as a powerful inhibitor of various serine proteases, specifically thrombin, but also trypsin. Addition of ethyl ester and hexyloxycarbonyl carbamide hydrophobic side chains led to the orally absorbed
prodrug. In order to improve the solubility of the prodrug its salts form was formulated as final drug product.
The chemical name for Dabigatran etexilate mesylate, is β-Alanine, N-[[2-[[[4-
[[[(hexyloxy)carbonyl]amino]iminomethyl] I ] ami no] methyl ] - 1 -methyl - 1 H- benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-,ethyl ester, methanesulfonate. The empirical formula is C34H41N7O5 · CH4O3S and the molecular weight is 723.86 (mesylate salt), 627.75 (free base). The structural formula is:
Dabigatran etexilate mesylate is a yellow-white to yellow powder. A saturated solution in pure water has a solubility of 1.8 mg/mL. It is freely soluble in methanol, slightly soluble in ethanol, and sparingly soluble in isopropanol.
Based on these physicochemical and biopharmaceutical properties of Dabigatran etexilate mesylate and the clinical requirements for a reliable drug release a multilayer pellet was developed. Other formulation approaches were evaluated during early development, but were inferior to the selected formulation in terms of drug load, stability and in vivo performance.
The active substance is susceptible to hydrolysis in presence of humidity under acidic conditions. Batch analysis results confirm that alkyl methane sulfonates (genotoxic impurities) that could potentially be formed during manufacturing are not formed at detectable levels during the manufacturing of the finished product. The 150 mg capsule (PRAXADA) for oral administration contains 172.95 mg Dabigatran etexilate mesylate, which is equivalent to 150 mg of Dabigatran etexilate, and the following pharmaceutically acceptable excipients: acacia, dimethicone, hypromellose, hydroxypropyl cellulose, talc, and tartaric acid. The capsule shell is composed of carrageenan, FD&C Blue No. 2 (150 mg only), FD&C Yellow No. 6, hypromellose, potassium chloride, titanium
dioxide, and black edible ink. The 75 mg capsule contains 86.48 mg dabigatran etexilate mesylate, equivalent to 75 mg Dabigatran etexilate, and is otherwise similar to the 150 mg capsule.
PRAXADA should be swallowed as a whole with water, with or without food. Patients have to be instructed not to open the capsule as this may increase the risk of bleeding.
Dabigatran and its acyl glucuronides are competitive, direct thrombin inhibitors. Because thrombin (serine protease) enables the conversion of fibrinogen into fibrin during the coagulation cascade, its inhibition prevents the development of a thrombus. Both free and clot-bound thrombin and thrombin-induced platelet aggregation are inhibited by the active moieties.
Dabigatran etexilate mesylate is absorbed as the Dabigatran etexilate ester. The ester is then hydrolyzed, forming Dabigatran, the active moiety. Dabigatran is metabolized to four different acyl glucuronides and both the glucuronides and Dabigatran have similar pharmacological activity. Pharmacokinetics described here refer to the sum of Dabigatran and its glucuronides. Dabigatran displays dose-proportional pharmacokinetics in healthy subjects and patients in the range of doses from 10 to 400 mg.
The absolute bioavailability of Dabigatran following oral administration of Dabigatran etexilate is approximately 3 to 7%. Dabigatran etexilate is a substrate of the efflux transporter P-gp. After oral administration of Dabigatran etexilate in healthy volunteers, Cmax occurs at 1 hour post-administration in the fasted state. Coadministration of PRADAXA with a high-fat meal delays the time to Cmax by approximately 2 hours but has no effect on the bioavailability of Dabigatran; PRADAXA may be administered with or without food.
The oral bioavailability of Dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation. PRADAXA capsules should therefore not be broken, chewed, or opened before administration.
Dabigatran is approximately 35% bound to human plasma proteins. The red blood cell to plasma partitioning of Dabigatran measured as total radioactivity is less than 0.3. The volume of distribution of Dabigatran is 50 to 70 L. Dabigatran pharmacokinetics are dose proportional after single doses of 10 to 400 mg. Given twice daily, Dabigatran's accumulation factor is approximately two.
Dabigatran is eliminated primarily in the urine. Renal clearance of Dabigatran is 80% of total clearance after intravenous administration. After oral administration of radiolabeled Dabigatran, 7% of radioactivity is recovered in urine and 86% in feces. The half-life of Dabigatran in healthy subjects is 12 to 17 hours.
After oral administration, Dabigatran etexilate is converted to Dabigatran. The cleavage of the Dabigatran etexilate by esterase-catalyzed hydrolysis to the active principal Dabigatran is the predominant metabolic reaction. Dabigatran is not a substrate, inhibitor, or inducer of CYP450 enzymes. Dabigatran is subject to conjugation forming pharmacologically active acyl glucuronides. Four positional isomers, 1-0, 2-0, 3-0, and 4-O-acylglucuronide exist, and each accounts for less than 10% of total Dabigatran in plasma.
The most commonly reported adverse reactions are bleedings occurring in total in approximately 16.5 % in patients with atrial fibrillation treated for the prevention of stroke and systemic embolic events. A dose response with respect to bleeding was seen for Dabigatran etexilate. Major or severe bleeding may occur and, regardless of location, may lead to disabling, life-threatening or even fatal outcomes.
The European Medicines Agency has recommended updating the product information for the blood thinner PRAXADA, to give clearer guidance to doctors and patients on how to reduce and manage the risk of bleeding associated with the anticoagulant medicine. Bleeding is a well-known complication of all anticoagulant medicines and PRAXADA has therefore been kept under close review by the Agency's Committee for Medicinal Products for Human Use (CHMP) since its initial authorization (25 May 2012, EMA/337406/2012).
FDA has not changed its recommendations regarding PRAXADA. PRAXADA provides an important health benefit when used as directed. Healthcare professionals who prescribe PRAXADA should carefully follow the dosing recommendations in the drug label, especially for patients with renal impairment (when kidneys don't function normally) to reduce the risk of bleeding. Patients with atrial fibrillation should not stop taking PRAXADA without first talking to their healthcare professional. Stopping use of anticoagulant medications such as PRAXADA can increase the risk of stroke. Strokes can lead to permanent disability and death (FDA Drug Safety Communication of 12/19/2012).
The solubility of the Dabigatran ester is pH sensitive. Below pH 4.2 its solubility is actually appreciable. Above this pH it decreases rapidly reaching practically insoluble levels in the 6-7 pH range.
Dabigatran etexilate is available in capsule form (PRADAXA). It is formulated together with tartaric acid to reduce the variability of Dabigatran etexilate absorption, which is dependent on an acid environment. A Dabigatran etexilate coating is applied onto a tartaric acid core to form tiny pellets (~lmm diameter). A single capsule contains hundreds of these pellets, the exact number depending on the dose strength of the capsule. In this way, Dabigatran etexilate absorption is independent of gastrointestinal tract acidity and is not materially affected by co- administration of a proton pump inhibitor. The oral bioavailability of Dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation. PRADAXA capsules should therefore not be broken, chewed, or opened before administration.
The low systemic oral bioavailability is attributed to the low solubility of the compound at physiologically relevant pH. The above formulation strategy ensures the absorption of the compound by creating a low pH milieu in the upper intestine (the first part of the duodenum) which dissolves the compound. At the lower parts of the GI track where pH is raised to the 6- 7 range the compound precipitates. This creates a short window (around 0.5 h) for the compound to get absorbed. As a result of this pH dependent solubility the absolute bioavailability of Dabigatran following oral administration of Dabigatran etexilate is approximately 3 to 7% even when using the above detailed formulation strategy. This makes it necessary to administer high doses which deliver substantial amount of tartaric acid and an anticoagulant to the GI tract. This results in GI tract bleeding as a very common adverse effect of the drug. The risk of major bleeds was similar with PRADAXA 150 mg and warfarin across major subgroups defined by baseline characteristics, with the exception of age, where there was a trend towards a higher incidence of major bleeding on PRADAXA (hazard ratio 1.2, 95% CI: 1.0 to 1.4) for patients >75 years of age. There was a higher rate of major gastrointestinal bleeds in patients receiving PRADAXA 150 mg than in patients receiving warfarin (1.6% vs. 1.1%, respectively, with a hazard ratio vs. warfarin of 1.5, 95% CI, 1.2 to 1.9), and a higher rate of any gastrointestinal bleeds (6.1% vs. 4.0%, respectively). It has been hypothesized that tartaric
acid may promote GI bleeding through caustic injury, this is likely to be the case because the anti-platelet medication Aggrenox® (aspirin and dipyridamole), which is formulated with similar amounts of tartaric acid, is also associated with increased GI bleeding.
A variety of strategies have been used to attempt to overcome these issues, see for example US 5, 145,684; US 5,518,187; US 5,862,999; US 5,718,388; US 6,431,478; US 6,582,285; US
6,742,734; US2006/0165806; WO2009/075401; US 8,092,785; WO2003/002258; US
7,951,399; US 7,575, 184; US 6,814,319; WO0032313; WO2011/131943; WO2012/042224,
WO2006/060698; WO2006/096462; US2006/0159766; US2006/0188566; WO2006/110811;
WO2002/000196; WO2001/085345; US 8,074,906; US 7,441,717; US 6,921,458; US 6,641,063; US 5,389,382; WO2000/040220; WO2010/146406; WO2010/146408;
WO2010/146409; WO2011/158053; WO2010/146407; WO2011/154755; WO2011/158052;
WO2009/133418; US 5,091, 187; US 6,607,784; US 5,780,062; US 5,560,932; US 4,540,602;
US 5, 133,908; US 5,716,642; US2002/0127278; US 7,244,451; US2005/020294;
WO2009/007992; WO2007/150030; US 6,018,080; WO2001/003670; US2002/0168402; WO2006/100281; US2006/0013888; US 5, 141,961; US 5,646, 131; US 4,894,235; US
2003/0104065; US 5,646, 131; US 6,596,263; US 6,699,849; EP1348432; US 5324718;
WO2000/016744; WO2005/037250; WO2012/160559; WO2006/021160; WO2008/002121;
WO2006/112541; US 8, 158,162; WO2010/133611; US 7,550, 158; US 6,706,283; US
8,354, 122; EP1027886; US 6,677,362; US 5,340,591; US 7,994,214; US 8,337,899; US 8,343,548; US 4,996,047; US 5,980,882; EP 0911039; US 6,436,912; US 6,458,347; US
6,291,671; US 5,324,718; US 6,699,849; US 6,406,713; US 4,687,762; US 4,489,065;
WO2003/086363; US2004/0224024; US2007/0110804; US 6,063,370; EP 0987023; US
7,537,786; CN102558153; WO2013124340; EP2588090; WO2012027543; EP2631234;
WO2011110876; EP2288335; WO2012044595; WO2010020601; WO2013110567; EP2328581 and US20100322870.
DESCRIPTION OF THE INVENTION
Disclosed herein is a stable complex comprising as active compound chosen from Dabigatran, its salts or derivatives thereof; and at least one complexation agent chosen from polyvinylcaprolactam-polyvinyl acetate-polyethylene-glycol graft copolymers and poloxamers; polyvinylpyrrolidone; polyoxyglicerides; copolymers of vinylpyrrolidone and
vinyl-acetate; and poly(maleic acid-co-methyl-vinyl-ether); said complex characterized in that it possesses at least one of the following properties: having a particle size in the range between 50 nm and 600 nm, preferably 50 nm and 300 nm;
is instantaneously redispersable in buffers in physiological pH range ;
is stable in solid form and in colloid solution and/or dispersion;
exhibits pH independent PAMPA permeability in the physiological pH range has a PAMPA permeability of at least 0.3* 10"6 cm/s when dispersed in FaSSIF or FeSSIF biorelevant media;
is characterized by infrared (ATR) spectrum having main/characteristic absorption peaks at 1730 cm"1, 1608 cm"1, 1468 cm"1, 1437 cm"1, 1384 cm"1, 1328 cm"1, 1252 cm"1, 1193 cm"1, 1144 cm"1, 1118 cm"1, 1098 cm"1, 1052 cm"1, 993 cm"1, 948 cm"1, 888 cm"1, 837 cm"1, 811 768 cm"1, 754 cm"1, 704 cm"1, 680 cm"1, 632 cm"1, 604 cm"1, 567 cm"1, 545 cm"1 and 524 cm"1, preferable at 1730 cm"1, 1608 cm"1, 1437 cm"1, 1328 cm"1,! 118 cm"1, 1098 cm"1, and 754 cm"1.
The invention is a complex formula having increased and pH independent permeability in the physiological relevant pH range and enhanced biological performance including higher Cmax and AUC, faster onset of action and decreased fed/fasted effect.
We have found that only selected combinations of complexation agents and pharmaceutically accepted excipients disclosed in the present invention result in a stable complex formula having improved physicochemical characteristics and enhanced biological performance.
The expression Dabigatran is generally used for Dabigatran, its esters, such as Dabigatran etexilate or its salts such as Dabigatran etexilate mesylate, Dabigatran etexilate methanesulfonate, Dabigatran etexilate bismesylate or derivatives of Dabigatran.
In an embodiment, said complexation agent is chosen from polyvinylcaprolactam-polyvinyl acetate-polyethylene-glycol graft copolymers and poloxamers; polyvinylpyrrolidone; polyoxyglicerides; copolymers of vinylpyrrolidone and vinyl-acetate; and poly(maleic acid- co-methyl -vinyl -ether) .
In an embodiment, said complex further comprises at least one pharmaceutically acceptable excipient selected from the group of sodium-acetate, sodium-lauryl-sulfate, dioctyl sodium sulfosuccinate, cetylpyridinium chloride and sodium saccharine.
In an embodiment, said complex has a controlled particle size in the range between 50 nm and 600 nm. In an embodiment, said particle size is between 50 nm and 300 nm.
In an embodiment, said complex further comprises one or more additional active agents.
In an embodiment, said additional active agent is chosen from agents useful for the prophylaxis of diseases, in particular thrombotic diseases, stroke, cardiac infarction and/or atrial fibrillation and cardiac arrhythmia, as well as oncological diseases of any pathogenesis. In an embodiment, said complex is orally available.
In an embodiment, said complex possesses at least two of the properties described in a) - f).
In an embodiment, said complex possesses at least three of the properties described in a) - f).
In an embodiment, said complex has an increased dissolution rate.
Further disclosed herein is a stable complex comprising an active compound selected from the group of Dabigatran, its salt, or derivatives thereof; at least one complexation agent chosen from polyvinylcaprolactam-polyvinyl acetate-polyethylene-glycol graft copolymers and poloxamers; polyvinylpyrrolidone; polyoxyglicerides; copolymers of vinylpyrrolidone and vinyl-acetate; and poly(maleic acid-co-methyl-vinyl-ether); and at least one pharmaceutically acceptable excipient chosen from sodium-acetate, sodium-lauryl-sulfate, dioctyl sodium sulfosuccinate, cetylpyridinium chloride and sodium saccharine; wherein said complex obtained via a mixing process.
In an embodiment, said complex is obtained via a continuous flow mixing process.
In an embodiment, a complex comprises a complexation agent and a pharmaceutically acceptable excipient in a total amount ranging from about 1.0 weight% to about 95.0 weight % based on the total weight of the complex.
In an embodiment, said complexation agent and pharmaceutically acceptable excipient comprise 50 weight% to about 95 weight% of the total weight of the complex.
Further disclosed herein is a process for the preparation of the complex, comprising the steps of mixing a solution of Dabigatran, its salt, or derivatives thereof; and at least one complexation agent chosen from polyvinylcaprolactam-polyvinyl acetate-polyethylene-glycol graft copolymers and poloxamers; polyvinylpyrrolidone; polyoxyglicerides; copolymers of vinylpyrrolidone and vinyl-acetate; and poly(maleic acid-co-methyl-vinyl-ether) in a pharmaceutically acceptable solvent with an aqueous solution containing and at least one pharmaceutically acceptable excipient chosen from sodium-acetate, sodium-lauryl-sulfate, dioctyl sodium sulfosuccinate, cetylpyridinium chloride and sodium saccharine.
In an embodiment, said process is performed in a continuous flow instrument. In an embodiment, said continuous flow instrument is a microfluidic flow instrument.
In an embodiment, said pharmaceutically acceptable solvent is chosen from methanol, ethanol, i-propanol, n-propanol, acetone, acetonitrile, dimethyl-sulfoxyde, or tetrahydrofuran, or combinations thereof.
In an embodiment, said pharmaceutically acceptable solvent and said aqueous solvent are miscible with each other.
In an embodiment, said aqueous solvent comprises 0.1 to 99.9% weight of the final solution.
In an embodiment, said aqueous solvent comprises 50 to 90% weight of the final solution.
In an embodiment, said aqueous solvent comprises 50 to 80% weight of the final solution.
In an embodiment, said aqueous solvent comprises 50 to 70% weight of the final solution. In an embodiment, said aqueous solvent comprises 50 to 60% weight of the final solution.
In an embodiment, said aqueous solvent comprises 50 % weight of the final solution.
In an embodiment, a pharmaceutical composition comprising the complex together with pharmaceutically acceptable carrier.
In an embodiment, said composition is suitable for oral, pulmonary, rectal, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, ocular, otic, local, buccal, nasal, or topical administration.
In an embodiment, said composition is suitable for oral administration.
In an embodiment, said complex is for use in the manufacture of a medicament for the treatment and/or prophylaxis of diseases, in particular thrombotic diseases, stroke, cardiac infarction and/or atrial fibrillation and cardiac arrhythmia, as well as oncological diseases of any pathogenesis.
In an embodiment, said complex is used for the treatment and/or prophylaxis of diseases, in particular thrombotic diseases, stroke, cardiac infarction and/or atrial fibrillation and cardiac arrhythmia, as well as oncological diseases of any pathogenesis.
In an embodiment, a method of treatment and/or prophylaxis of diseases, in particular thrombotic diseases, stroke, cardiac infarction and/or atrial fibrillation and cardiac arrhythmia, as well as oncological diseases of any pathogenesis comprises administration of a therapeutically effective amount of a complex or a pharmaceutical composition as described herein.
In an embodiment, a method for reducing the therapeutically effective dosage of Dabigatran compared to orally available formulations comprises oral administration of a pharmaceutical composition as described herein.
Further disclosed herein is a stable complex wherein said complex has a controlled particle size in the range between 50 nm and 600 nm; and wherein said complex is not obtained via a milling process or by high pressure homogenization process, encapsulation process and solid dispersion process, but it is obtained by a mixing process, preferable continuous flow mixing process.
In an embodiment, said particle size is between 50 nm and 300 nm.
In an embodiment, said complex shows reduced fed/fasted effect based on in vivo studies.
In an embodiment, said complex shows significantly improved exposure, earlier tmax, higher Cmax which will allow the oral administration and reduction of the dose.
In an embodiment, said complex has a faster onset of action compared to the marketed formulations.
In an embodiment, said complex is instantaneously redispersable in physiological relevant media.
In an embodiment, said complex is stable in solid form and in colloid solution and/or dispersion. In an embodiment, said complex exhibits pH independent PAMPA permeability in the physiological pH range.
In an embodiment, said complex has a PAMPA permeability of at least 0.3* 10"6 cm/s when dispersed in FaSSIF or FeSSIF biorelevant media
In an embodiment, said complex is characterized by infrared (ATR) spectrum having charateristic absorption peaks at 1730 cm"1, 1608 cm"1, 1468 cm"1, 1437 cm"1, 1384 cm"1, 1328 cm"1, 1252 cm"1, 1193 cm"1, 1144 cm"1, 1118 cm"1, 1098 cm"1, 1052 cm"1, 993 cm"1, 948 cm"1, 888 cm"1, 837 cm"1, 811 768 cm"1, 754 cm"1, 704 cm"1, 680 cm"1, 632 cm"1, 604 cm"1, 567 cm"1, 545 cm"1 and 524 cm"1, preferable at 1730 cm"1, 1608 cm"1, 1437 cm"1, 1328 cm"1,! 118 cm"1, 1098 cm"1, and 754 cm"1. In an embodiment, said complex has decreased incidence of GI tract bleeding adverse side effect when compared to the marketed form.
The complexation agents and pharmaceutically acceptable excipients of the Dabigatran complex formulae of the invention are selected from the group of pharmaceutically acceptable nonionic, anionic, cationic, ionic polymers, surfactants and other types of excipients. The complexation agents themselves or together with the pharmaceutically accepted excipients have the function to form a complex structure with an active pharmaceutical ingredient through non-covalent secondary interactions. The secondary interactions can form through electrostatic interactions such as ionic interactions, H-bonding, dipole-dipole interactions, dipole-induced dipole interactions, London dispersion forces, π-π interactions, and hydrophobic interactions. The complexation agents, pharmaceutically accepted excipients and active ingredients are selected from the group of complexation agents, pharmaceutically accepted excipients and active ingredients which are able to form such complex structures through non-covalent secondary interactions.
In some embodiments, the compositions may additionally include one or more pharmaceutically acceptable excipients, auxiliary materials, carriers, active agents or combinations thereof. In some embodiments, active agents may include agents useful for the treatment and/or prophylaxis of diseases, in particular thrombotic diseases, stroke, cardiac infarction and/or atrial fibrillation and cardiac arrhythmia, as well as oncological diseases of any pathogenesis.
Another aspect of the invention is the complex formulae of the Dabigatran with complexation agents and pharmaceutically acceptable excipients in which the complexation agents and pharmaceutically acceptable excipients preferably are associated or interacted with the Dabigatran especially as the results of the mixing process, preferably continuous flow mixing process. In some embodiment, the structure of the complex Dabigatran formula is different from the core-shell type milled particle, precipitated encapsulated particles, micelles and solid dispersions.
The pharmaceutical composition of the invention can be formulated: (a) for administration selected from the group consisting of oral, pulmonary, rectal, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, ocular, otic, local, buccal, nasal, and topical administration; (b) into a dosage form selected from the group consisting of liquid dispersions, gels, aerosols, ointments, creams, lyophilized formulations, tablets, capsules; (c) into a dosage form selected from the group consisting of controlled release formulations, fast melt formulations, delayed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations; or (d) any combination of (a), (b), and (c).
The compositions can be formulated by adding different types of excipients for oral administration in solid, liquid, local (powders, ointments or drops), or topical administration, and the like.
The compositions can be formulated by adding different types of pharmaceutically acceptable excipients for oral administration in solid, liquid, local (powders, ointments or drops), or topical administration, and the like.
A preferred dosage form of the invention is a solid dosage form, although any pharmaceutically acceptable dosage form can be utilized.
Solid dosage forms for oral administration include, but are not limited to, capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active agent is admixed with at least one of the following excipients: (a) one or more inert excipients (or carriers), such as sodium citrate or dicalcium phosphate; (b) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, microcrystalline cellulose and silicic acid; (c) binders, such as cellulose derivatives, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (d) humectants, such as glycerol; (e) disintegrating agents, such as crospovidon, sodium starch glycolate, effervescent compositions, croscarmellose sodium,, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates and sodium carbonate; (f) solution retarders, such as acrylates, cellulose derivatives, paraffin; (g) absorption accelerators, such as quaternary ammonium compounds; (h) wetting agents, such as polysorbates, cetyl alcohol and glycerol monostearate; (i) adsorbents, such as kaolin and bentonite; and j) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. For capsules, tablets, and pills, the dosage forms may also comprise buffering agents.
Besides such inert diluents, the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Advantages of the complex Dabigatran formulae of the invention include, but are not limited to (1) physical and chemical stability, (2) instantaneous redispersibility, (3) stability in colloid solution or dispersion in the therapeutic time window, (4) increased solubility compared to the conventional Dabigatran formulation at physiologically relevant pH, (5) increased and pH independent permeability in the physiological relevant pH range, (6) possibility of dose reduction, (7) reduced GI tract bleeding adverse effect due to decreased anticoagulant dose and no strong acid necessary to be added to the formula and (8) good processability. Beneficial features of the present invention are as follows: the good/instantaneous redispersibility of solid complex formulae of Dabigatran in water, biologically relevant media, e.g.; physiological saline solution, pH=2.5 HC1 solution, FessiF and FassiF media and gastro intestinal fluids and adequate stability in colloid solutions and/or dispersion in the therapeutic time window. One of the preferred characteristics of the complex Dabigatran formulae of the present invention is their increased apparent solubility and pH independent increased permeability. In
some embodiments, the permeability of the complex Dabigatran formulae is at least 0.574* 10" 6 cm/s, 0.376* 10"6 cm/s and 0.421 * 10"6 cm/s in the 5-8.5 pH range, respectively.
Finally, the invention relates to a method for the treatment of a subject in need for the treatment and/or prophylaxis of diseases, in particular thrombotic diseases, stroke, cardiac infarction and/or atrial fibrillation and cardiac arrhythmia, as well as oncological diseases of any pathogenesisby administering to the subject an effective amount of the complex or the pharmaceutical composition according to the invention.
Another preferred characteristic of the complex Dabigatran formulae of the present invention relates to the enhanced pharmacokinetic performance of the complex Dabigatran formulae. The complex Dabigatran is available for absorption in the whole GI tract extending the window for absorption from 0.5 hour to 4-5 hours and allows safer administration of a lower dose from the active ingredient.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1. shows complexation agent and pharmaceutically acceptable excipient screening for formula selection
Figure 2. shows particle size of the redispersed solid complex of the selected formula Figure 3. shows SEM photos of complex Dabigatran (A) and placebo sample (B)
Figure 4. shows infrared (ATR) spectra of Crystalline Dabigatran etexilate (A), amorphous Dabigatran etexilate (B), complex Dabigatran exeilate (C), placebo (D), Gelucire 44/14 (E), CPC (F) and Sacharine (G)
Figure 5. shows comparative PAMPA assays of complex Dabigatran formula and the marketed compound (Pradaxa)
Figure 6. shows pharmacokinetic properties of Dabigatran following the oral administration of Pradaxa (granules from the capsule) and complex Dabigatran Etexilate (dispersed in pH 8.5 Tris buffer) in rats in the fasted state at 3 mg/kg dose (n=4)
EXAMPLES
1. Selection of complexation agents and pharmaceutically accepted stabilizers for the production of complex Dabigatran formulae
Several pharmaceutically accepted complexation agents and pharmaceutically accepted excipients and their combinations were tested in order to select the formulae having instantaneous redispersibility as shown in Figure 1. One of the examples that displayed an acceptable level of redispersibility was selected for further analysis.
2. Process for producing stable colloid solution and or dispersion of solid complex Dabigatran formula
A colloid solution of Dabigatran complex formula with the optimal ratio of the pharmaceutically acceptable excipients of the present invention was prepared by continuous flow mixing in a flow instrument. As a starting solution, 200 mg Dabigatran etexilate and 600 mg polyoxygliceride (Gelucire 44/14) dissolved in 100 mL tetrahydrofuran was used. The prepared solution was passed into the instrument with 2 mL/min flow rate. Meanwhile, aqueous solvent containing 50 mg cetylpyridinium chloride and 250 mg sodium saccharine in 500 mL water was passed into the instrument with 8 mL/min flow rate, where Dabigatran formed complex Dabigatran composition. The colloid solution of the complex Dabigatran is continuously produced at atmospheric pressure. The produced colloid solution was frozen on dry-ice and then it was lyophilized using a freeze drier equipped with -110°C ice condenser, with a vacuum pump. Particle size of complex Dabigatran was measured in reconstituted colloid solution right after the lyophilisation. It was found to be 156 nm as shown in Figure 2.
3. Structural analysis
Morphology of complex Dabigatran etexilate of Example 2 was investigated using FEI Quanta 3D scanning electron microscope. The morphology of the complex of the present invention was compared to the placebo sample prepared in the lack of Dabigatran etexilate. Complex Dabigatran of the present invention consists of spherical particles. In the lack of the active compound, the pharmaceutically acceptable excipients do not form spherical particles as shown in Figure 3.
Structural analysis was performed by using Bruker Vertex 70 FT-IR spectrometer with Bruker Platinum diamond ATR unit. Continuous flow mixing of Dabigatran etexilate in the presence of selected complexation agents and pharmaceutically accepted excipients, such as polyoxygliceride (Gelucire 44/14), cetylpyridinium chloride and sodium saccharine resulted in a stable complex of Dabigatran as shown in Figure 4. In a preferred embodiment the complex or the pharmaceutical composition according to the invention characterized by at least one of the following characteristic infrared (ATR ) peak at 1730 cm"1, 1608 cm"1, 1468 cm"1, 1437 cm"1, 1384 cm"1, 1328 cm"1, 1252 cm"1, 1193 cm"1, 1144 cm"1, 1118 cm"1, 1098 cm" 1052 cm"1, 993 cm"1, 948 cm"1, 888 cm"1, 837 cm"1, 811 768 cm"1, 754 cm"1, 704 cm"1, 680 cm"1, 632 cm"1, 604 cm"1, 567 cm_1,_545 cm"1 and 524 cm"1, preferable at 1730 cm"1, 1608 cm" cm"1, 1328 cm"1, 1118 cm"1, 1098 cm"1, and 754 cm"1.
4. Comparative in vitro PAMPA assays
PAMPA permeability measurements were performed as described by M. Kansi et al. (Journal of medicinal chemistry, 41, (1998) pp 1007) with modifications based on S. Bendels et al (Pharmaceutical research, 23 (2006) pp 2525). Sample containing the reference compound was a suspension of crystals visible by the naked eye, while samples of the novel complex were opalescent colloid solutions. Permeability was measured in a 96-well plate assay across an artificial membrane composed of dodecane with 20% soy lecithin supported by a PVDF membrane (Millipore, USA). The receiver compartment was phosphate buffered saline (pH 7.0) supplemented with 1% sodium dodecyl sulfate. The assay was performed at room temperature; incubation time was 1-24 hours. The concentration in the receiver compartment was determined by UV-VIS spectrophotometry (Thermo Scientific Genesys S10).
PAMPA permeability of complex Dabigatran formula of Example 2 was 0.574* 10"6 cm/s, 0.376* 10"6 cm/s and 0.421 * 10"6 cm/s when dispersed in a buffer pH 5.0, 6.5 or 8.5, respectively, while permeability of the marketed compound (Pradaxa) was 0.094* 10"6 cm/s, 0.060* 10"6 cm/s and 0.020* 10"6 cm/s when dispersed in the same buffers as shown in Figure 5.
5. Comparative in vivo study The main objective of this study was the pharmacokinetic evaluation of a Dabigatran etexilate complex formulation following a single oral administration at 3 mg/kg dose to jugular vein
cannulated male Wistar rats. The mean metabolite, Dabigatran was measured in plasma using a reliable LC/MS6MS method.
The test item substance was formulated in 0.1M Tris buffer (pH=8.5). The test item was administered to the rats orally by gavage. The granules of the reference item were administered through a plastic gavage into the stomach of the rats. The granules were pushed out with the help of a mandrin then water was administered in a same amount as the test item administration amount.
Blood was collected in the following time points using sodium heparin as anticoagulant: 15m, 30m, 45m, lh, 1.5h, 2h, 4h, 6h, and 8h. The plasma was separated and stored in an ultra- freezer (below -70°C) until analysis.
Dabigatran plasma kinetics showed high inter-individual variability after dosing the reference item. After dosing of the reference item the shape of the individual curves and the tmax values (0.25h - 4h) showed very high variability and the Cmax values varied in a range (80.6 ± 37.0).
For the test item peak concentrations of Dabigatran occurred at 0.25h - 0.5h after administration in all the four rats. The average Cmax value was 210 ± 154 ng/ml. The elimination of Dabigatran from the plasma was relatively fast: the mean half-life was 1.60 ± 0.291 h. The AUCinf values were 470 ± 243 ng*h/ml. This total exposure of the complex formulation was compared to the AUCinf value obtained for a reference formulation (Pradaxa) after administration of the same oral dose of Dabigatran etexilate. The AUCinf of Pradaxa was 280 ± 93.7 ng*h/ml. The relative oral bioavailability (Frel) of the investigated nano- formulation proved to be 168% (Figure 6).
Claims
1. A stable complex comprising as active compound selected from the group of Dabigatran, its esters, preferably Dabigatran etexilate, its salts, preferably Dabigatran etexilate mesylate, or derivatives thereof; and at least one complexation agent selected from the group of a polyvinylcaprolactam-polyvinyl acetate-polyethylene-glycol graft copolymers and poloxamers; polyvinylpyrrolidone; polyoxyglicerides; copolymers of vinylpyrrolidone and vinyl-acetate; and poly(maleic acid-co-methyl-vinyl-ether); said complex characterized in that it possesses at least one of the following properties: a) having a particle size in the range between 50 nm and 600 nm, preferably 50 nm and 300 nm;
b) is instantaneously redispersable in buffers in physiological pH range ;
c) is stable in solid form and in colloid solution and/or dispersion;
d) exhibits pH independent PAMPA permeability in the physiological pH range e) has a PAMPA permeability of at least 0.3* 10"6 cm/s when dispersed in FaSSIF or FeSSIF biorelevant media;
f) is characterized by infrared (ATR) spectrum having main/characteristic absorption peaks at 1730 cm"1, 1608 cm"1, 1437 cm"1, 1328 cm"1,! 118 cm"1, 1098 cm"1, and 754 cm"1;
g) has reduced fed/fasted effect based on in vivo studies.
h) has significantly improved exposure, earlier tmax, higher Cmax which will allow the oral administration and reduction of the dose.
i) has a faster onset of action compared to the marketed formulations.
2. The complex according to Claim 1, wherein said complexation agent is selected from the group of polyvinylcaprolactam-polyvinyl acetate-polyethylene-glycol graft copolymers and poloxamers; polyvinylpyrrolidone; polyoxyglicerides; copolymers of vinylpyrrolidone and vinyl-acetate; and poly(maleic acid-co-methyl-vinyl-ether).
3. A complex according to Claims 1 or 2, wherein said complex further comprises at least one pharmaceutically accepted excipient selected from the group of sodium-lauryl-sulfate;
dioctyl sodium sulfosuccinate; cetylpyridinium chloride, sodium-acetate and sodium saccharine, preferably cetylpyridinium chloride and sodium saccharine.
The complex according to any of Claims 1 to 3, wherein said complex further comprises one or more additional active agents, preferable the additional active agent is selected from the group of agents useful for the treatment and/or prophylaxis of diseases, in particular thrombotic diseases, stroke, cardiac infarction and/or atrial fibrillation and cardiac arrhythmia, as well as oncological diseases of any pathogenesis.
The complex according to Claim 1, wherein said complex is orally bioavailable.
A stable complex according to any Claims 1 to 5comprising an active compound selected from the group of Dabigatran, its esters, preferably Dabigatran etexilate, its salts, preferably Dabigatran etexilate mesylate, or derivatives thereof; at least one complexation agent selected from the group of a polyvinylcaprolactam-polyvinyl acetate-polyethylene- glycol graft copolymers and poloxamers; polyvinylpyrrolidone; polyoxyglicerides; copolymers of vinylpyrrolidone and vinyl-acetate; and poly(maleic acid-co-methyl-vinyl- ether), and at least one pharmaceutically accepted excipient chosen from the group of sodium-lauryl-sulfate; dioctyl sodium sulfosuccinate; cetylpyridinium chloride, sodium- acetate and sodium saccharine; wherein said complex obtained via a mixing process, preferable continuous flow mixing process, more preferable microfluidic flow mixing process.
A complex according to Claims 1 to 6 comprising complexation agents selected from the group of polyvinylcaprolactam-polyvinyl acetate-polyethylene-glycol graft copolymers and/or poloxamers and/or polyvinylpyrrolidone and/or copolymers of vinylpyrrolidone and vinyl-acetate and/or polyoxyglicerides and pharmaceutically accepted excipients selected from the group of sodium-acetate and/or sodium-lauryl-sulfate and/or dioctyl sodium sulfosuccinate and/or cetylpyridinium chloride and/or sodium saccharine in an amount ranging from about 1.0 weight% to about 90.0 weight % based on the total weight of the complex.
A process for the preparation of the complex according to Claims 1 to 6, comprising the steps of mixing a solution of Dabigatran, its esters, preferably Dabigatran etexilate, its salts, preferably Dabigatran etexilate mesylate, or derivatives thereof, and at least one
complexation agent selected from the group of polyvinylcaprolactam-polyvinyl acetate- polyethylene-glycol graft copolymers and/or poloxamers and/or polyvinylpyrrolidone and/or copolymers of vinylpyrrolidone and vinyl-acetate and/or polyoxyglicerides in a pharmaceutically acceptable solvent with an aqueous solution containing at least one pharmaceutically accepted excipient chosen from sodium-acetate, sodium-lauryl-sulfate, dioctyl sodium sulfosuccinate, cetylpyridinium chloride and sodium saccharine..
9. The process according to Claim 7, wherein said process is performed in a continuous flow instrument, preferable in microfluidic instrument.
10. The process according to Claims 7 or 8, wherein said pharmaceutically acceptable solvent is selected from the group of methanol, ethanol, isopropanol, n-propanol, acetone, acetonitrile, dimethyl-sulfoxide, tetrahydrofuran, and combinations thereof.
11. The process according to any of Claims 7 to 9, wherein the solvent and the aqueous solvent are miscible with each other and the aqueous solvent comprises 0.1 to 99.9% weight of the final solution.
12. A pharmaceutical composition comprising the complex according to any of Claims 1 to 6 together with pharmaceutically acceptable carrier.
13. A pharmaceutical composition according to Claim 11, wherein said composition is suitable for oral, pulmonary, rectal, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, ocular, otic, local, buccal, nasal, or topical administration, preferable the composition is suitable for oral administration.
14. A complex according to any of Claims 1 or to 6 for use in the manufacture of a medicament for the treatment and/or prophylaxis of diseases, in particular thrombotic diseases, stroke, cardiac infarction and/or atrial fibrillation and cardiac arrhythmia, as well as oncological diseases of any pathogenesis.
15. The use of the complex according to any of Claims 1 or to 6 for the treatment and/or prophylaxis of diseases, in particular thrombotic diseases, stroke, cardiac infarction and/or atrial fibrillation and cardiac arrhythmia, as well as oncological diseases of any pathogenesis.
16. A method of treatment and/or prophylaxis of diseases, in particular thrombotic diseases, stroke, cardiac infarction and/or atrial fibrillation and cardiac arrhythmia, as well as oncological diseases of any pathogenesis comprising administration of a therapeutically effective amount of the complex according to any of Claims 1 to 6 or the pharmaceutical composition according to Claim 12 orl3.
17. A stable complex wherein said complex has a controlled particle size in the range between 50 nm and 600 nm, preferable the particle size is between 50 nm and 300 nm; and wherein said complex is obtained according to any of claims 7 to 11.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUP1300648 | 2013-11-12 | ||
HU1300648A HUP1300648A2 (en) | 2013-11-12 | 2013-11-12 | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
HUP1400084 | 2014-02-17 | ||
HU1400084A HUP1400084A2 (en) | 2014-02-17 | 2014-02-17 | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical composition containing them |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015071841A1 true WO2015071841A1 (en) | 2015-05-21 |
Family
ID=89991406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2014/065992 WO2015071841A1 (en) | 2013-11-12 | 2014-11-12 | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015071841A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105534939A (en) * | 2015-12-29 | 2016-05-04 | 郑州大明药物科技有限公司 | Dabigatran etexilate mesylate oral solid preparation and preparation method thereof |
WO2017187336A1 (en) * | 2016-04-25 | 2017-11-02 | Druggability Technologies Ip Holdco Limited | Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
WO2017187340A1 (en) * | 2016-04-25 | 2017-11-02 | Druggability Technologies Ip Holdco Limited | Pharmaceutical combination composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them |
WO2017187338A1 (en) * | 2016-04-25 | 2017-11-02 | Druggability Technologies Ip Holdco Limited | Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
US10376501B2 (en) | 2016-04-25 | 2019-08-13 | Druggability Technologies Ip Holdco Limited | Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
US10383865B2 (en) | 2016-04-25 | 2019-08-20 | Druggability Technologies Ip Holdco Limited | Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them |
CN111163807A (en) * | 2017-09-19 | 2020-05-15 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | Lipophilic peptide prodrugs |
CN111902161A (en) * | 2018-04-04 | 2020-11-06 | 上海汉都医药科技有限公司 | Pharmaceutical composition containing dabigatran etexilate and preparation method thereof |
CN113893356A (en) * | 2020-11-27 | 2022-01-07 | 上海博志研新药物技术有限公司 | Dabigatran etexilate mesylate inclusion compound, preparation method and application |
US11965041B2 (en) | 2017-09-19 | 2024-04-23 | Technische Universitaet Muenchen | N-methylated cyclic peptides and their prodrugs |
Citations (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4489065A (en) | 1981-07-02 | 1984-12-18 | Valcor Scientific Ltd. | Chondroitin drug Complexes |
US4540602A (en) | 1979-04-13 | 1985-09-10 | Freund Industry Company, Limited | Process for the preparation of activated pharmaceutical compositions |
US4687762A (en) | 1984-03-31 | 1987-08-18 | Green Cross Corporation | Water soluble drug complex and method for production of same |
WO1989008127A1 (en) * | 1988-02-29 | 1989-09-08 | Gaf Chemicals Corporation | Solubilization of complexes of water-insoluble organic compounds by aqueous solutions of polyvinylpyrrolidone |
US4894235A (en) | 1984-10-23 | 1990-01-16 | Dr. Rentschler, Arzneimmittel Gmbh & Co. | Nifedipine-containing form of administration and method for its production |
US4996047A (en) | 1988-11-02 | 1991-02-26 | Richardson-Vicks, Inc. | Sustained release drug-resin complexes |
US5091187A (en) | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
US5133908A (en) | 1986-12-31 | 1992-07-28 | Centre National De La Recherche Scientifique (Cnrs) | Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles |
US5141961A (en) | 1991-06-27 | 1992-08-25 | Richrdson-Vicks Inc. | Process for solubilizing difficulty soluble pharmaceutical actives |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5324718A (en) | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
US5389382A (en) | 1986-12-19 | 1995-02-14 | Sandoz Ltd. | Hydrosols of pharmacologically active agents and their pharmaceutical compositions comprising them |
US5518187A (en) | 1992-11-25 | 1996-05-21 | Nano Systems L.L.C. | Method of grinding pharmaceutical substances |
US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
US5646131A (en) | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
US5716642A (en) | 1995-01-10 | 1998-02-10 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents |
US5718388A (en) | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
US5780062A (en) | 1994-11-09 | 1998-07-14 | The Ohio State University Research Foundation | Small particle formation |
US5862999A (en) | 1994-05-25 | 1999-01-26 | Nano Systems L.L.C. | Method of grinding pharmaceutical substances |
EP0911039A2 (en) | 1997-04-16 | 1999-04-28 | Medeva Pharmaceutical Manufacturing, Inc. | Drug-resin complexes stabilized by chelating agents |
US6018080A (en) | 1992-12-24 | 2000-01-25 | Glaxo Wellcome Inc. | Atovaquone pharmaceutical compositions |
EP0987023A1 (en) | 1997-04-17 | 2000-03-22 | Panacea Biotec Limited | Transition metal complexes of non steroidal anti-inflammatory drugs |
WO2000016744A1 (en) | 1998-09-23 | 2000-03-30 | Guju Pharm. Co., Ltd. | A pharmaceutical solution for the treatment of erectile dysfunction, prepared by sedds formulation |
US6063370A (en) | 1996-04-05 | 2000-05-16 | The Board Of Trustees Of The University Of Illinois | Macromolecular complexes for drug delivery |
WO2000032313A1 (en) | 1998-12-01 | 2000-06-08 | Aventis Pharma Limited | Milling process for the production of finely milled medicinal substances |
WO2000040220A1 (en) | 1999-01-06 | 2000-07-13 | Korea Research Institute Of Chemical Technology | Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same |
EP1027886A2 (en) | 1999-02-10 | 2000-08-16 | Pfizer Products Inc. | Pharmaceutical solid dispersions |
WO2001003670A1 (en) | 1999-07-13 | 2001-01-18 | Pharmasol Gmbh | Method for controlled production of ultrafine microparticles and nanoparticles |
US6291671B1 (en) | 1996-06-06 | 2001-09-18 | Daiichi Pharmaceutical Co., Ltd. | Process for producing drug complexes |
WO2001085345A1 (en) | 2000-05-10 | 2001-11-15 | Rtp Pharma Inc. | Media milling |
WO2002000196A2 (en) | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
US6406713B1 (en) | 1987-03-05 | 2002-06-18 | The Liposome Company, Inc. | Methods of preparing low-toxicity drug-lipid complexes |
US6431478B1 (en) | 1999-06-01 | 2002-08-13 | Elan Pharma International Limited | Small-scale mill and method thereof |
US6436912B1 (en) | 1996-06-06 | 2002-08-20 | Daiichi Pharmaceutical Co., Ltd. | Drug complexes |
US20020127278A1 (en) | 2000-12-22 | 2002-09-12 | Kipp James E. | Microprecipitation method for preparing submicron suspensions |
US6458347B1 (en) | 1996-04-15 | 2002-10-01 | Asahi Kasei Kabushiki Kaisha | Drug complex |
WO2003002258A1 (en) | 2001-06-29 | 2003-01-09 | Eurand Pharmaceuticals Ltd | Drug activation process and vibrational mill therefor |
US20030104065A1 (en) | 2000-03-09 | 2003-06-05 | Arne Brodin | Method of preparing solid dispersions |
US6582285B2 (en) | 2000-04-26 | 2003-06-24 | Elan Pharmainternational Ltd | Apparatus for sanitary wet milling |
US6596263B1 (en) | 1995-07-14 | 2003-07-22 | Stc English Ideas, Inc. | Cyclodextrin compositions |
EP1348432A1 (en) | 2001-01-04 | 2003-10-01 | Daiichi Pharmaceutical Co., Ltd. | Cyclodextrin-containing pharmaceutical preparation |
WO2003086363A1 (en) | 2002-04-08 | 2003-10-23 | Lavipharm Laboratories Inc. | Drug-complex microparticles and methods of making/using same |
US6641063B2 (en) | 1998-12-01 | 2003-11-04 | Aventis Pharma Limited | Milling process for the production of finely milled medicinal substances |
US6677362B1 (en) | 1991-12-18 | 2004-01-13 | Warner-Lambert Company | Solid pharmaceutical dispersions |
US6699849B1 (en) | 1998-02-23 | 2004-03-02 | Cyclops, Ehf. | Cyclodextrin complexes of benzodiazepines |
US6706283B1 (en) | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
US6742734B2 (en) | 2001-06-05 | 2004-06-01 | Elan Pharma International Limited | System and method for milling materials |
US6814319B2 (en) | 2000-12-06 | 2004-11-09 | Pharmacia & Upjohn Company | Laboratory scale milling process |
US20040224024A1 (en) | 2003-04-23 | 2004-11-11 | Massachusetts Institute Of Technology | Controlled drug release formulations containing polyion complexes |
US20050020294A1 (en) | 2001-12-07 | 2005-01-27 | Marko Kantola | System for transmitting information in a digital radio network system |
WO2005037250A1 (en) | 2003-10-17 | 2005-04-28 | Amylin Pharmaceuticals, Inc. | Self emulsifying drug delivery systems for hydrophobic therapeutic compounds |
US6921458B2 (en) | 2002-12-19 | 2005-07-26 | Acusphere, Inc. | Methods and apparatus for making particles using spray dryer and in-line jet mill |
US20060013888A1 (en) | 2003-09-29 | 2006-01-19 | Ronald G. Udell | Solubilized CoQ-10 |
WO2006021160A1 (en) | 2004-08-27 | 2006-03-02 | Shijiazhuang Pharma. Group Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Butylbenzene phthalein self-emulsifying drug delivery system, its preparation method and application |
WO2006060698A1 (en) | 2004-12-03 | 2006-06-08 | Elan Pharma International Ltd. | Nanoparticulate benzothiophene formulations |
US20060159766A1 (en) | 2004-12-15 | 2006-07-20 | Elan Pharma International Limited | Nanoparticulate tacrolimus formulations |
US20060165806A1 (en) | 2005-01-06 | 2006-07-27 | Elan Pharma International Limited | Nanoparticulate candesartan formulations |
US20060188566A1 (en) | 2005-02-24 | 2006-08-24 | Elan Pharma International Limited | Nanoparticulate formulations of docetaxel and analogues thereof |
WO2006096462A1 (en) | 2005-03-03 | 2006-09-14 | Elan Pharma International Limited | Nanoparticulate compositions of heterocyclic amide derivatives |
WO2006100281A2 (en) | 2005-03-22 | 2006-09-28 | Losan Pharma Gmbh | Solubilized ibuprofen |
WO2006110811A1 (en) | 2005-04-12 | 2006-10-19 | Elan Pharma International Limited | Nanoparticulate quinazoline derivative formulations |
WO2006112541A1 (en) | 2005-04-20 | 2006-10-26 | Chugai Seiyaku Kabushiki Kaisya | Method for the design of self-emulsifying drug formulations |
US20070110804A1 (en) | 2003-06-20 | 2007-05-17 | Royer Biomedical, Inc. | Drug polymer complexes |
US7244451B2 (en) | 2000-09-21 | 2007-07-17 | Elan Pharma International Ltd. | Methods of making nanoparticulate drug compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers |
WO2007150030A2 (en) | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
WO2008002121A2 (en) | 2006-06-28 | 2008-01-03 | Hovid, Berhad | A self-emulsifying composition for poorly bioavailable drugs |
US7441717B1 (en) | 2007-10-31 | 2008-10-28 | Eastman Kodak Company | Micromedia milling process |
WO2009007992A2 (en) | 2007-04-20 | 2009-01-15 | Sun Pharmaceutical Industries Limited | Pharmaceutical composition produced by microprecipitation |
US7537786B2 (en) | 2005-02-25 | 2009-05-26 | Nec Corporation | Complex of drug-carbon nanohorn and a process for producing the complex |
WO2009075401A1 (en) | 2007-12-12 | 2009-06-18 | Chung-Ang University Industry-Academy Cooperation Foundation | Manufacturing method of functional drug nanoparticles using milling and functional drug nanoparticle formulation manufactured thereby |
WO2009118322A1 (en) * | 2008-03-28 | 2009-10-01 | Boehringer Ingelheim International Gmbh | Process for preparing orally administered dabigatran formulations |
WO2009133418A1 (en) | 2008-04-28 | 2009-11-05 | Nangenex Nanotechnology Incorporated | Instrument and process for nanoparticles production in continuous flow mode |
WO2010020601A1 (en) | 2008-08-19 | 2010-02-25 | Boehringer Ingelheim International Gmbh | Dabigatran in tumour therapy |
WO2010133611A1 (en) | 2009-05-18 | 2010-11-25 | Royal College Of Surgeons In Ireland | Solid drug dispersions |
WO2010146406A1 (en) | 2009-06-19 | 2010-12-23 | Nanoform Hungary Ltd. | Nanoparticulate telmisartan compositions and process for the preparation thereof |
US20100322870A1 (en) | 2008-11-11 | 2010-12-23 | Boehringer Ingelheim International Gmbh | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy |
WO2010146408A2 (en) | 2009-06-19 | 2010-12-23 | Nangenex, Inc. | Nanoparticulate olmesartan medoxomil compositions, process for the preparation thereof and pharmaceutical compositions containing them |
WO2010146407A1 (en) | 2009-06-19 | 2010-12-23 | Nanoform Hungary Ltd. | Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them |
WO2010146409A2 (en) | 2009-06-19 | 2010-12-23 | Nangenex, Inc. | Nanoparticulate candesartan cilexetil compositions, process for the preparation thereof and pharmaceutical compositions containing them |
US7951399B2 (en) | 2001-06-29 | 2011-05-31 | Eurand Pharmaceuticals Ltd. | Process for activation of drugs in a vibrational mill |
EP2328581A1 (en) | 2008-08-19 | 2011-06-08 | Boehringer Ingelheim International GmbH | Use of dabigatranetexilate for treating patients with pulmonary hypertension |
US7994214B2 (en) | 2003-08-29 | 2011-08-09 | Lifecycle Pharma A/S | Solid dispersions comprising tacrolimus |
WO2011110876A1 (en) | 2010-02-02 | 2011-09-15 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Novel salts for the manufacture of pharmaceutical compositions |
WO2011110478A1 (en) * | 2010-03-08 | 2011-09-15 | Ratiopharm Gmbh | Dabigatran etexilate-containing pharmaceutical composition |
WO2011131943A2 (en) | 2010-04-20 | 2011-10-27 | Cipla Limited | Pharmaceutical compositions |
US8074906B2 (en) | 2005-07-07 | 2011-12-13 | Nanotherapeutics, Inc. | Process for milling and preparing powders and compositions produced thereby |
WO2011154755A1 (en) | 2010-06-08 | 2011-12-15 | Nanoform Cardiovascular Therapeutics Ltd. | Nanostructured atorvastatin, its pharmaceutically acceptable salts and compositions of them, process for the preparation thereof and pharmaceutical compositions containing them |
WO2011158053A1 (en) | 2010-06-18 | 2011-12-22 | Nanoform Cardiovascular Therapeutics Ltd. | Nanostructured aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them |
WO2011158052A1 (en) | 2010-06-18 | 2011-12-22 | Nanoform Cardiovascular Therapeutics Ltd. | Nanostructured ezetimibe compositions, process for the preparation thereof and pharmaceutical compositions containing them |
US8092785B2 (en) | 2004-08-23 | 2012-01-10 | Glaxo Group Limited | Process for milling poorly soluble drugs in presence of liquid propellants |
WO2012027543A1 (en) | 2010-08-25 | 2012-03-01 | Teva Pharmaceuticals Usa, Inc. | Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof |
WO2012042224A2 (en) | 2010-10-01 | 2012-04-05 | Cipla Limited | Pharmaceutical composition |
WO2012044595A1 (en) | 2010-09-27 | 2012-04-05 | Ratiopharm Gmbh | Dabigatran etexilate bismesylate salt, solid state forms and process for preparation thereof |
US8158162B2 (en) | 2001-11-14 | 2012-04-17 | Jarrow Formulas, Inc. | Eutectic-based self-nanoemulsified drug delivery system |
CN102558153A (en) | 2012-02-08 | 2012-07-11 | 北京阜康仁生物制药科技有限公司 | Novel pharmaceutical salt of dabigatran etexilate and preparation method thereof |
WO2012160559A1 (en) | 2011-05-22 | 2012-11-29 | Rappaport Family Institute For Research In The Medical Sciences | Pharmaceutical compositions of d-alpha-tocopheryl acetate |
US8337899B2 (en) | 1997-08-11 | 2012-12-25 | Bend Research, Inc. | Solid pharmaceutical dispersions with enhanced bioavailability |
US8343548B2 (en) | 2006-08-08 | 2013-01-01 | Shin-Etsu Chemical Co., Ltd. | Solid dosage form comprising solid dispersion |
US8354122B2 (en) | 2006-04-20 | 2013-01-15 | Shin-Etsu Chemical Co., Ltd. | Solid dispersion preparation |
EP2588090A2 (en) | 2010-07-01 | 2013-05-08 | Krka Tovarna Zdravil, D.D., Novo Mesto | Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts |
WO2013110567A1 (en) | 2012-01-24 | 2013-08-01 | Boehringer Ingelheim International Gmbh | Novel orally administered dabigatran formulation |
EP2631234A1 (en) | 2012-02-23 | 2013-08-28 | Esteve Química, S.A. | Solid forms of dabigatran etexilate mesylate and processes for their preparation |
WO2013124340A1 (en) | 2012-02-21 | 2013-08-29 | Laboratorios Del Dr. Esteve, S.A. | Oral pharmaceutical compositions of dabigatran etexilate |
WO2013175494A2 (en) * | 2012-04-10 | 2013-11-28 | Rubicon Research Private Limited | Controlled release pharmaceutical formulations of direct thrombin inhibitors |
WO2014131376A1 (en) * | 2013-02-26 | 2014-09-04 | Elmarco S.R.O. | Electrospun nanofibers comprising pharmaceutically active agents |
-
2014
- 2014-11-12 WO PCT/IB2014/065992 patent/WO2015071841A1/en active Application Filing
Patent Citations (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4540602A (en) | 1979-04-13 | 1985-09-10 | Freund Industry Company, Limited | Process for the preparation of activated pharmaceutical compositions |
US4489065A (en) | 1981-07-02 | 1984-12-18 | Valcor Scientific Ltd. | Chondroitin drug Complexes |
US4687762A (en) | 1984-03-31 | 1987-08-18 | Green Cross Corporation | Water soluble drug complex and method for production of same |
US4894235A (en) | 1984-10-23 | 1990-01-16 | Dr. Rentschler, Arzneimmittel Gmbh & Co. | Nifedipine-containing form of administration and method for its production |
US5389382A (en) | 1986-12-19 | 1995-02-14 | Sandoz Ltd. | Hydrosols of pharmacologically active agents and their pharmaceutical compositions comprising them |
US5133908A (en) | 1986-12-31 | 1992-07-28 | Centre National De La Recherche Scientifique (Cnrs) | Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles |
US6406713B1 (en) | 1987-03-05 | 2002-06-18 | The Liposome Company, Inc. | Methods of preparing low-toxicity drug-lipid complexes |
WO1989008127A1 (en) * | 1988-02-29 | 1989-09-08 | Gaf Chemicals Corporation | Solubilization of complexes of water-insoluble organic compounds by aqueous solutions of polyvinylpyrrolidone |
US4996047A (en) | 1988-11-02 | 1991-02-26 | Richardson-Vicks, Inc. | Sustained release drug-resin complexes |
US5091187A (en) | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5141961A (en) | 1991-06-27 | 1992-08-25 | Richrdson-Vicks Inc. | Process for solubilizing difficulty soluble pharmaceutical actives |
US6677362B1 (en) | 1991-12-18 | 2004-01-13 | Warner-Lambert Company | Solid pharmaceutical dispersions |
US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
US5324718A (en) | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
US5518187A (en) | 1992-11-25 | 1996-05-21 | Nano Systems L.L.C. | Method of grinding pharmaceutical substances |
US6018080A (en) | 1992-12-24 | 2000-01-25 | Glaxo Wellcome Inc. | Atovaquone pharmaceutical compositions |
US5646131A (en) | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
US5718388A (en) | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
US5862999A (en) | 1994-05-25 | 1999-01-26 | Nano Systems L.L.C. | Method of grinding pharmaceutical substances |
US5780062A (en) | 1994-11-09 | 1998-07-14 | The Ohio State University Research Foundation | Small particle formation |
US5716642A (en) | 1995-01-10 | 1998-02-10 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents |
US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
US6596263B1 (en) | 1995-07-14 | 2003-07-22 | Stc English Ideas, Inc. | Cyclodextrin compositions |
US6063370A (en) | 1996-04-05 | 2000-05-16 | The Board Of Trustees Of The University Of Illinois | Macromolecular complexes for drug delivery |
US6458347B1 (en) | 1996-04-15 | 2002-10-01 | Asahi Kasei Kabushiki Kaisha | Drug complex |
US6291671B1 (en) | 1996-06-06 | 2001-09-18 | Daiichi Pharmaceutical Co., Ltd. | Process for producing drug complexes |
US6436912B1 (en) | 1996-06-06 | 2002-08-20 | Daiichi Pharmaceutical Co., Ltd. | Drug complexes |
EP0911039A2 (en) | 1997-04-16 | 1999-04-28 | Medeva Pharmaceutical Manufacturing, Inc. | Drug-resin complexes stabilized by chelating agents |
US5980882A (en) | 1997-04-16 | 1999-11-09 | Medeva Pharmaceuticals Manufacturing | Drug-resin complexes stabilized by chelating agents |
EP0987023A1 (en) | 1997-04-17 | 2000-03-22 | Panacea Biotec Limited | Transition metal complexes of non steroidal anti-inflammatory drugs |
US8337899B2 (en) | 1997-08-11 | 2012-12-25 | Bend Research, Inc. | Solid pharmaceutical dispersions with enhanced bioavailability |
US6699849B1 (en) | 1998-02-23 | 2004-03-02 | Cyclops, Ehf. | Cyclodextrin complexes of benzodiazepines |
WO2000016744A1 (en) | 1998-09-23 | 2000-03-30 | Guju Pharm. Co., Ltd. | A pharmaceutical solution for the treatment of erectile dysfunction, prepared by sedds formulation |
WO2000032313A1 (en) | 1998-12-01 | 2000-06-08 | Aventis Pharma Limited | Milling process for the production of finely milled medicinal substances |
US6641063B2 (en) | 1998-12-01 | 2003-11-04 | Aventis Pharma Limited | Milling process for the production of finely milled medicinal substances |
WO2000040220A1 (en) | 1999-01-06 | 2000-07-13 | Korea Research Institute Of Chemical Technology | Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same |
US6706283B1 (en) | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
US7550158B2 (en) | 1999-02-10 | 2009-06-23 | Bend Research, Inc. | Controlled release by extrusion of solid amorphous dispersions of drugs |
EP1027886A2 (en) | 1999-02-10 | 2000-08-16 | Pfizer Products Inc. | Pharmaceutical solid dispersions |
US6431478B1 (en) | 1999-06-01 | 2002-08-13 | Elan Pharma International Limited | Small-scale mill and method thereof |
WO2001003670A1 (en) | 1999-07-13 | 2001-01-18 | Pharmasol Gmbh | Method for controlled production of ultrafine microparticles and nanoparticles |
US20030104065A1 (en) | 2000-03-09 | 2003-06-05 | Arne Brodin | Method of preparing solid dispersions |
US6582285B2 (en) | 2000-04-26 | 2003-06-24 | Elan Pharmainternational Ltd | Apparatus for sanitary wet milling |
WO2001085345A1 (en) | 2000-05-10 | 2001-11-15 | Rtp Pharma Inc. | Media milling |
WO2002000196A2 (en) | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
US7244451B2 (en) | 2000-09-21 | 2007-07-17 | Elan Pharma International Ltd. | Methods of making nanoparticulate drug compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers |
US6814319B2 (en) | 2000-12-06 | 2004-11-09 | Pharmacia & Upjohn Company | Laboratory scale milling process |
US20020168402A1 (en) | 2000-12-22 | 2002-11-14 | Kipp James E. | Microprecipitation method for preparing submicron suspensions |
US20020127278A1 (en) | 2000-12-22 | 2002-09-12 | Kipp James E. | Microprecipitation method for preparing submicron suspensions |
US6607784B2 (en) | 2000-12-22 | 2003-08-19 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
EP1348432A1 (en) | 2001-01-04 | 2003-10-01 | Daiichi Pharmaceutical Co., Ltd. | Cyclodextrin-containing pharmaceutical preparation |
US6742734B2 (en) | 2001-06-05 | 2004-06-01 | Elan Pharma International Limited | System and method for milling materials |
US7575184B2 (en) | 2001-06-05 | 2009-08-18 | Elan Pharma International Ltd. | System and method for milling materials |
WO2003002258A1 (en) | 2001-06-29 | 2003-01-09 | Eurand Pharmaceuticals Ltd | Drug activation process and vibrational mill therefor |
US7951399B2 (en) | 2001-06-29 | 2011-05-31 | Eurand Pharmaceuticals Ltd. | Process for activation of drugs in a vibrational mill |
US8158162B2 (en) | 2001-11-14 | 2012-04-17 | Jarrow Formulas, Inc. | Eutectic-based self-nanoemulsified drug delivery system |
US20050020294A1 (en) | 2001-12-07 | 2005-01-27 | Marko Kantola | System for transmitting information in a digital radio network system |
WO2003086363A1 (en) | 2002-04-08 | 2003-10-23 | Lavipharm Laboratories Inc. | Drug-complex microparticles and methods of making/using same |
US6921458B2 (en) | 2002-12-19 | 2005-07-26 | Acusphere, Inc. | Methods and apparatus for making particles using spray dryer and in-line jet mill |
US20040224024A1 (en) | 2003-04-23 | 2004-11-11 | Massachusetts Institute Of Technology | Controlled drug release formulations containing polyion complexes |
US20070110804A1 (en) | 2003-06-20 | 2007-05-17 | Royer Biomedical, Inc. | Drug polymer complexes |
US7994214B2 (en) | 2003-08-29 | 2011-08-09 | Lifecycle Pharma A/S | Solid dispersions comprising tacrolimus |
US20060013888A1 (en) | 2003-09-29 | 2006-01-19 | Ronald G. Udell | Solubilized CoQ-10 |
WO2005037250A1 (en) | 2003-10-17 | 2005-04-28 | Amylin Pharmaceuticals, Inc. | Self emulsifying drug delivery systems for hydrophobic therapeutic compounds |
US8092785B2 (en) | 2004-08-23 | 2012-01-10 | Glaxo Group Limited | Process for milling poorly soluble drugs in presence of liquid propellants |
WO2006021160A1 (en) | 2004-08-27 | 2006-03-02 | Shijiazhuang Pharma. Group Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Butylbenzene phthalein self-emulsifying drug delivery system, its preparation method and application |
WO2006060698A1 (en) | 2004-12-03 | 2006-06-08 | Elan Pharma International Ltd. | Nanoparticulate benzothiophene formulations |
US20060159766A1 (en) | 2004-12-15 | 2006-07-20 | Elan Pharma International Limited | Nanoparticulate tacrolimus formulations |
US20060165806A1 (en) | 2005-01-06 | 2006-07-27 | Elan Pharma International Limited | Nanoparticulate candesartan formulations |
US20060188566A1 (en) | 2005-02-24 | 2006-08-24 | Elan Pharma International Limited | Nanoparticulate formulations of docetaxel and analogues thereof |
US7537786B2 (en) | 2005-02-25 | 2009-05-26 | Nec Corporation | Complex of drug-carbon nanohorn and a process for producing the complex |
WO2006096462A1 (en) | 2005-03-03 | 2006-09-14 | Elan Pharma International Limited | Nanoparticulate compositions of heterocyclic amide derivatives |
WO2006100281A2 (en) | 2005-03-22 | 2006-09-28 | Losan Pharma Gmbh | Solubilized ibuprofen |
WO2006110811A1 (en) | 2005-04-12 | 2006-10-19 | Elan Pharma International Limited | Nanoparticulate quinazoline derivative formulations |
WO2006112541A1 (en) | 2005-04-20 | 2006-10-26 | Chugai Seiyaku Kabushiki Kaisya | Method for the design of self-emulsifying drug formulations |
US8074906B2 (en) | 2005-07-07 | 2011-12-13 | Nanotherapeutics, Inc. | Process for milling and preparing powders and compositions produced thereby |
US8354122B2 (en) | 2006-04-20 | 2013-01-15 | Shin-Etsu Chemical Co., Ltd. | Solid dispersion preparation |
WO2007150030A2 (en) | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
WO2008002121A2 (en) | 2006-06-28 | 2008-01-03 | Hovid, Berhad | A self-emulsifying composition for poorly bioavailable drugs |
US8343548B2 (en) | 2006-08-08 | 2013-01-01 | Shin-Etsu Chemical Co., Ltd. | Solid dosage form comprising solid dispersion |
WO2009007992A2 (en) | 2007-04-20 | 2009-01-15 | Sun Pharmaceutical Industries Limited | Pharmaceutical composition produced by microprecipitation |
US7441717B1 (en) | 2007-10-31 | 2008-10-28 | Eastman Kodak Company | Micromedia milling process |
WO2009075401A1 (en) | 2007-12-12 | 2009-06-18 | Chung-Ang University Industry-Academy Cooperation Foundation | Manufacturing method of functional drug nanoparticles using milling and functional drug nanoparticle formulation manufactured thereby |
WO2009118322A1 (en) * | 2008-03-28 | 2009-10-01 | Boehringer Ingelheim International Gmbh | Process for preparing orally administered dabigatran formulations |
EP2288335A1 (en) | 2008-03-28 | 2011-03-02 | Boehringer Ingelheim International GmbH | Process for preparing orally administered dabigatran formulations |
WO2009133418A1 (en) | 2008-04-28 | 2009-11-05 | Nangenex Nanotechnology Incorporated | Instrument and process for nanoparticles production in continuous flow mode |
WO2010020601A1 (en) | 2008-08-19 | 2010-02-25 | Boehringer Ingelheim International Gmbh | Dabigatran in tumour therapy |
EP2328581A1 (en) | 2008-08-19 | 2011-06-08 | Boehringer Ingelheim International GmbH | Use of dabigatranetexilate for treating patients with pulmonary hypertension |
US20100322870A1 (en) | 2008-11-11 | 2010-12-23 | Boehringer Ingelheim International Gmbh | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy |
WO2010133611A1 (en) | 2009-05-18 | 2010-11-25 | Royal College Of Surgeons In Ireland | Solid drug dispersions |
WO2010146407A1 (en) | 2009-06-19 | 2010-12-23 | Nanoform Hungary Ltd. | Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them |
WO2010146409A2 (en) | 2009-06-19 | 2010-12-23 | Nangenex, Inc. | Nanoparticulate candesartan cilexetil compositions, process for the preparation thereof and pharmaceutical compositions containing them |
WO2010146408A2 (en) | 2009-06-19 | 2010-12-23 | Nangenex, Inc. | Nanoparticulate olmesartan medoxomil compositions, process for the preparation thereof and pharmaceutical compositions containing them |
WO2010146406A1 (en) | 2009-06-19 | 2010-12-23 | Nanoform Hungary Ltd. | Nanoparticulate telmisartan compositions and process for the preparation thereof |
WO2011110876A1 (en) | 2010-02-02 | 2011-09-15 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Novel salts for the manufacture of pharmaceutical compositions |
WO2011110478A1 (en) * | 2010-03-08 | 2011-09-15 | Ratiopharm Gmbh | Dabigatran etexilate-containing pharmaceutical composition |
WO2011131943A2 (en) | 2010-04-20 | 2011-10-27 | Cipla Limited | Pharmaceutical compositions |
WO2011154755A1 (en) | 2010-06-08 | 2011-12-15 | Nanoform Cardiovascular Therapeutics Ltd. | Nanostructured atorvastatin, its pharmaceutically acceptable salts and compositions of them, process for the preparation thereof and pharmaceutical compositions containing them |
WO2011158052A1 (en) | 2010-06-18 | 2011-12-22 | Nanoform Cardiovascular Therapeutics Ltd. | Nanostructured ezetimibe compositions, process for the preparation thereof and pharmaceutical compositions containing them |
WO2011158053A1 (en) | 2010-06-18 | 2011-12-22 | Nanoform Cardiovascular Therapeutics Ltd. | Nanostructured aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them |
EP2588090A2 (en) | 2010-07-01 | 2013-05-08 | Krka Tovarna Zdravil, D.D., Novo Mesto | Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts |
WO2012027543A1 (en) | 2010-08-25 | 2012-03-01 | Teva Pharmaceuticals Usa, Inc. | Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof |
WO2012044595A1 (en) | 2010-09-27 | 2012-04-05 | Ratiopharm Gmbh | Dabigatran etexilate bismesylate salt, solid state forms and process for preparation thereof |
WO2012042224A2 (en) | 2010-10-01 | 2012-04-05 | Cipla Limited | Pharmaceutical composition |
WO2012160559A1 (en) | 2011-05-22 | 2012-11-29 | Rappaport Family Institute For Research In The Medical Sciences | Pharmaceutical compositions of d-alpha-tocopheryl acetate |
WO2013110567A1 (en) | 2012-01-24 | 2013-08-01 | Boehringer Ingelheim International Gmbh | Novel orally administered dabigatran formulation |
CN102558153A (en) | 2012-02-08 | 2012-07-11 | 北京阜康仁生物制药科技有限公司 | Novel pharmaceutical salt of dabigatran etexilate and preparation method thereof |
WO2013124340A1 (en) | 2012-02-21 | 2013-08-29 | Laboratorios Del Dr. Esteve, S.A. | Oral pharmaceutical compositions of dabigatran etexilate |
EP2631234A1 (en) | 2012-02-23 | 2013-08-28 | Esteve Química, S.A. | Solid forms of dabigatran etexilate mesylate and processes for their preparation |
WO2013175494A2 (en) * | 2012-04-10 | 2013-11-28 | Rubicon Research Private Limited | Controlled release pharmaceutical formulations of direct thrombin inhibitors |
WO2014131376A1 (en) * | 2013-02-26 | 2014-09-04 | Elmarco S.R.O. | Electrospun nanofibers comprising pharmaceutically active agents |
Non-Patent Citations (5)
Title |
---|
GAREKANI H A ET AL: "Increasing the aqueous solubility of acetaminophen in the presence of polyvinylpyrrolidone and investigation of the mechanisms involved", DRUG DEV IND PHARM, vol. 29, no. 2, February 2003 (2003-02-01), pages 173 - 179, XP002735410 * |
M. KANSI ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, 1998, pages 1007 |
S. BENDELS ET AL., PHARMACEUTICAL RESEARCH, vol. 23, 2006, pages 2525 |
SARAVANA KUMAR K ET AL: "Dissolution Enhancement of Poorly Soluble Drugs by Using Complexation Technique - A Review", J. PHARM. SCI. & RES., vol. 5, no. 5, May 2013 (2013-05-01), pages 120 - 124, XP002735411 * |
T. REINTJES: "Solubility Enhancement with BASF Pharma Polymers: Solubilizer Compendium", October 2011 (2011-10-01), XP002735409, Retrieved from the Internet <URL:http://www.pharma-ingredients.basf.com/Documents/ENP/Brochure/EN/b_03_110921e_Solubility_Enhance_Compendium.pdf> [retrieved on 20150203] * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105534939A (en) * | 2015-12-29 | 2016-05-04 | 郑州大明药物科技有限公司 | Dabigatran etexilate mesylate oral solid preparation and preparation method thereof |
US10383865B2 (en) | 2016-04-25 | 2019-08-20 | Druggability Technologies Ip Holdco Limited | Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them |
US10376501B2 (en) | 2016-04-25 | 2019-08-13 | Druggability Technologies Ip Holdco Limited | Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
WO2017187338A1 (en) * | 2016-04-25 | 2017-11-02 | Druggability Technologies Ip Holdco Limited | Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
CN109475548A (en) * | 2016-04-25 | 2019-03-15 | 成药技术Ip控股有限公司 | According to cutting down the compound of Kato and its salt and derivative, preparation method and containing their pharmaceutical composition |
CN109475547A (en) * | 2016-04-25 | 2019-03-15 | 成药技术Ip控股有限公司 | The compound of Lu Makatuo and its salt and derivative, preparation method and the pharmaceutical composition containing them |
CN109475546A (en) * | 2016-04-25 | 2019-03-15 | 成药技术Ip控股有限公司 | Including according to the pharmaceutical combination composition for the compound formulation for cutting down Kato and Lu Makatuo and its salt and derivative, preparation method and containing their pharmaceutical composition |
WO2017187340A1 (en) * | 2016-04-25 | 2017-11-02 | Druggability Technologies Ip Holdco Limited | Pharmaceutical combination composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them |
WO2017187336A1 (en) * | 2016-04-25 | 2017-11-02 | Druggability Technologies Ip Holdco Limited | Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
CN111163807A (en) * | 2017-09-19 | 2020-05-15 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | Lipophilic peptide prodrugs |
US11965041B2 (en) | 2017-09-19 | 2024-04-23 | Technische Universitaet Muenchen | N-methylated cyclic peptides and their prodrugs |
CN111902161A (en) * | 2018-04-04 | 2020-11-06 | 上海汉都医药科技有限公司 | Pharmaceutical composition containing dabigatran etexilate and preparation method thereof |
EP3777892A4 (en) * | 2018-04-04 | 2021-06-02 | Shanghai WD Pharmaceutical Co., Ltd | Pharmaceutical composition containing dabigatran etexilate and preparation method thereof |
US11707455B2 (en) | 2018-04-04 | 2023-07-25 | Shanghai Wd Pharmaceutical Co., Ltd | Pharmaceutical composition containing dabigatran etexilate and preparation method thereof |
CN111902161B (en) * | 2018-04-04 | 2023-12-15 | 上海汉都医药科技有限公司 | Pharmaceutical composition containing dabigatran etexilate and preparation method thereof |
CN113893356A (en) * | 2020-11-27 | 2022-01-07 | 上海博志研新药物技术有限公司 | Dabigatran etexilate mesylate inclusion compound, preparation method and application |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015071841A1 (en) | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
ES2627820T3 (en) | Histone deacetylase inhibitor formulations in combination with bendamustine and uses thereof | |
CN103282036B (en) | For treating the composition and method of myelofibrosis | |
WO2008072535A1 (en) | Pharmaceutical composition containing low-substituted hydroxypropylcellulose | |
TW201731509A (en) | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
EA015102B1 (en) | Nanoparticulate imatinib mesylate formulations | |
EP3522872B1 (en) | Amlodipine formulations | |
WO2004054574A1 (en) | Solid drug for oral use | |
US20230338287A1 (en) | Amlodipine formulations | |
JP2012530127A (en) | Nanoparticulate candesartan cilexetil composition, process for its preparation and pharmaceutical composition containing them | |
JP2012530126A (en) | Nanoparticulate olmesartan medoxomil composition, method for its preparation, and pharmaceutical composition containing them | |
ES2706067T3 (en) | A pharmaceutical composition containing candesartan cilexetil and amlodipine | |
KR20160128449A (en) | Pharmaceutical preparation containing calcium antagonist/angiotensin ii receptor antagonist | |
CN101653440B (en) | Treatment composition containing amlodipine series salt and pril medicament | |
AU2006257428B2 (en) | Oral solid pharmaceutical formulation of the tubulin inhibitor indibulin | |
CN101468002A (en) | Therapeutic composition containing amlodipine salt and losartan medicine | |
AU2017382160A1 (en) | Pharmaceutical formulations of suvorexant | |
WO2002067904A1 (en) | Pharmaceutical composition which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer | |
CN103006648A (en) | Maleic acid levorotation amlodipine drug active pharmaceutical composition and preparation method thereof | |
EP2839835B1 (en) | Encapsulated formulation | |
CN101433536A (en) | Therapeutic compositions containing amlodipine niacin and losartan medicament | |
NO317771B1 (en) | Eprosartanarginyl charge neutralization complex and a process for its preparation and use thereof | |
US10376501B2 (en) | Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
CN102327220B (en) | Solid loratadine lipidosome preparation | |
WO2007091253A2 (en) | Pharmaceutical compositions comprising clopidogrel and vitamins which reduce homocysteine levels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14815023 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14815023 Country of ref document: EP Kind code of ref document: A1 |